Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 4, 2026

Citadel CEO criticizes Trump’s Fed attacks, warning they could have ‘steep costs.’ Here’s how to protect your portfolio

View original at finance.yahoo.com
Citadel CEO criticizes Trump’s Fed attacks, warning they could have ‘steep costs.’ Here’s how to protect your portfolio Fabrice Coffrini / Getty Images: Samuel Corum / Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • January was the most volatile month in precious metals history

    80% confidence

  • The District of Columbia criminal investigation is unprecedented

    80% confidence

  • Multifamily investment fundamentals remain solid amid ongoing economic and interest rate uncertainty

    80% confidence

  • S&P 500 will deliver annualized returns between 3.9% to 5.9% over the next 10 years

    80% confidence

  • Trump's strategy of publicly criticizing the Fed, suggesting dismissal of governors and pressuring the central bank to adopt a more permissive stance toward inflation carries steep costs

    80% confidence

  • The criminal investigation charges are a result of setting interest rates based on best assessment of what will serve the public rather than aligning with political interests

    80% confidence

  • December 2026 gold price forecast is $5,400 per ounce, up 15% from early February spot price

    80% confidence

  • Inflation remains somewhat elevated

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Citadel CEO criticizes Trump’s Fed attacks, warning they could have ‘steep costs.’ Here’s how to protect your portfolio — Source | Via News | ViaNews Market